In a 55-year-old man with uncontrolled hypertension and chronic kidney disease stage 2, which intervention most effectively delays progression to end‑stage renal disease?

Blood Pressure Control is the Most Effective Intervention

For a 55-year-old man with uncontrolled hypertension and CKD stage 2, blood pressure control (Option B) is the single most important intervention to delay progression to ESRD. This recommendation is strongly supported by multiple high-quality guidelines and represents the cornerstone of nephroprotection in this clinical scenario.

Why Blood Pressure Control Takes Priority

The evidence is unequivocal across all major guidelines:

• Target BP <130/80 mmHg for patients with CKD 1, 2, 3, 4
• Blood pressure control has Grade A evidence for slowing CKD progression 4
• The 2017 ACC/AHA guidelines specifically recommend BP <130/80 mmHg for all CKD patients based on SPRINT trial data, which included 28% of patients with stage 3-4 CKD 1

The mechanism is clear: Uncontrolled hypertension accelerates glomerular damage through increased intraglomerular pressure and hyperfiltration, creating a vicious cycle of progressive nephron loss 3. Controlling BP breaks this cycle.

Specific Treatment Algorithm

For this patient with stage 2 CKD (eGFR 60-89 mL/min/1.73m²) and uncontrolled hypertension:

1. First-line agents: ACE inhibitor or ARB 2, 3, 4, 1

   • These provide both BP control AND additional renoprotection beyond BP lowering alone
   • Use maximum tolerated doses 3

2. Add combination therapy (most patients need 3+ agents) 3:

   • Thiazide or thiazide-like diuretic (effective even in stage 2-3 CKD) 5, 6
   • Calcium channel blocker (dihydropyridine type) 3

3. Monitor closely: Check BP, eGFR, and potassium within 4 weeks of initiation or dose changes 3

Why the Other Options Are Inferior

A. Restricted protein diet (0.8 g/kg/day): While this has Grade B evidence 7, 4, it is:

• Less effective than BP control
• Primarily recommended for more advanced CKD (stage 3b or higher with declining GFR)
• Risk of malnutrition if implemented too early 8
• In stage 2 CKD, standard protein intake is acceptable; restriction becomes relevant only when GFR begins substantial decline 4

C. Early administration of HD: This is completely inappropriate. Dialysis is indicated only when eGFR <15 mL/min/1.73m² (stage 5) or when eGFR <30 with specific complications 7. Starting dialysis early in stage 2 CKD would cause harm without benefit.

D. High salt diet: This is contraindicated. Salt restriction to <2 grams sodium/day is recommended to:

• Improve BP control 8
• Reduce proteinuria 8
• Enhance effectiveness of RAAS inhibitors 8, 3

Critical Implementation Points

Common pitfalls to avoid:

• Failing to achieve target BP <130/80 mmHg (occurs in >50% of CKD patients in practice)
• Using inadequate doses of ACE inhibitors/ARBs
• Not monitoring potassium and creatinine after starting RAAS inhibitors (expect 20-30% creatinine rise initially, which is acceptable if stable) 3
• Avoiding thiazide diuretics in stage 2-3 CKD due to outdated beliefs about their ineffectiveness 6

Monitoring schedule 3:

• BP, eGFR, potassium: within 4 weeks of any medication change
• Once stable: every 3-6 months for stage 2 CKD
• More frequent if potassium >4.5 mEq/L on RAAS inhibitor

Contemporary Additions to Consider

While not among the answer choices, newer evidence supports adding 9, 10, 11:

• SGLT-2 inhibitors (dapagliflozin, empagliflozin) for additional cardio-renal protection
• Nonsteroidal MRAs (finerenone) to potentiate RAAS blockade 12

These agents complement—but do not replace—the fundamental importance of achieving BP control.

Bottom line: In this patient with uncontrolled hypertension and stage 2 CKD, achieving BP control to <130/80 mmHg using ACE inhibitor/ARB-based combination therapy is the most evidence-based intervention to prevent progression to ESRD. The other options are either premature (protein restriction, dialysis) or harmful (high salt diet).